Literature DB >> 19076155

Variability in the quality of overdose advice in Summary of Product Characteristics (SPC) documents: gut decontamination recommendations for CNS drugs.

Andrew J B Wall1, D N Bateman, W S Waring.   

Abstract

AIMS: Deliberate self-poisoning is a major cause of morbidity and mortality. The Summary of Product Characteristics (SPC) document is a legal requirement for all drugs, and Section 4.9 addresses the features of toxicity and clinical advice on management of overdose. The quality and appropriateness of this advice have received comparatively little attention.
METHODS: Section 4.9 of the SPC was examined for all drugs in the central nervous system (CNS) category of the British National Formulary. Advice concerning gut decontamination was examined with respect to specific interventions: induced vomiting, oral activated charcoal, gastric lavage, and other interventions. Data were compared with standard reference sources for clinical management advice in poisoning. These were graded 'A' if no important differences existed, 'B' if differences were noted but not thought clinically important, and 'C' if differences were thought to be clinically significant.
RESULTS: SPC documents were examined for 258 medications from 67 manufacturers. The overall agreement was 'A' in 23 (8.9%), 'B' in 28 (10.9%) and 'C' in 207 (80.2%). Discrepancies were due to inappropriate recommendation of induced emesis in 21.7% (95% confidence interval 17.1, 27.1), gastric lavage in 38.4% (32.7, 44.4), other gut decontamination in 5.8% (3.6, 9.4) and failure to recommend oral activated charcoal in 57.4% (51.1, 63.4).
CONCLUSIONS: Gut decontamination advice in SPC documents with respect to CNS drugs was inadequate. Possible reasons for the observed discrepancies and ways of improving the consistency of advice are proposed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19076155      PMCID: PMC2668088          DOI: 10.1111/j.1365-2125.2008.03322.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Methodology for the analysis and representation of the medical information about drugs in the Summary of Product Characteristics (SPC).

Authors:  A Venot; C Duclos
Journal:  Proc AMIA Symp       Date:  1999

2.  The epidemiology of self-poisoning in the UK.

Authors:  D R Camidge; R J Wood; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 3.  Trends in clinical toxicology: advances that may change your practice.

Authors:  Sage W Wiener; Robert S Hoffman
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-07       Impact factor: 4.080

4.  Incorrect overdose management advice in the Physicians' Desk Reference.

Authors:  W H Mullen; I B Anderson; S Y Kim; P D Blanc; K R Olson
Journal:  Ann Emerg Med       Date:  1997-02       Impact factor: 5.721

Review 5.  Position statement: ipecac syrup. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.

Authors:  E P Krenzelok; M McGuigan; P Lheur
Journal:  J Toxicol Clin Toxicol       Date:  1997

Review 6.  Position statement: gastric lavage. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.

Authors:  J A Vale
Journal:  J Toxicol Clin Toxicol       Date:  1997

Review 7.  Position paper: Single-dose activated charcoal.

Authors:  P A Chyka; D Seger; E P Krenzelok; J A Vale
Journal:  Clin Toxicol (Phila)       Date:  2005       Impact factor: 4.467

Review 8.  Position paper: gastric lavage.

Authors:  J A Vale; K Kulig
Journal:  J Toxicol Clin Toxicol       Date:  2004

9.  Survey of cases of paracetamol overdose in the UK referred to National Poisons Information Service (NPIS) consultants.

Authors:  H K R Thanacoody; A M Good; W S Waring; D N Bateman
Journal:  Emerg Med J       Date:  2008-03       Impact factor: 2.740

10.  Teaching application of clinical pharmacology skills using unusual observations from clozapine overdoses.

Authors:  P Timothy Pollak; Steven L Shafer
Journal:  J Clin Pharmacol       Date:  2004-02       Impact factor: 3.126

View more
  9 in total

1.  Clinical relevance of information in the Summaries of Product Characteristics for dose adjustment in renal impairment.

Authors:  Teresa M Salgado; Blanca Arguello; Fernando Martinez-Martinez; Shalom I Benrimoj; Fernando Fernandez-Llimos
Journal:  Eur J Clin Pharmacol       Date:  2013-07-25       Impact factor: 2.953

2.  Worldwide analysis of factors associated with medicines compendia publishing.

Authors:  Blanca Arguello; Fernando Fernandez-Llimos
Journal:  Int J Clin Pharm       Date:  2013-03-28

3.  Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.

Authors:  J Reis-Pardal; A Rodrigues; E Rodrigues; F Fernandez-Llimos
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

Review 4.  Citalopram and cardiac toxicity.

Authors:  M J Cooke; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

5.  Physicians' reported needs of drug information at point of care in Sweden.

Authors:  Pia Bastholm Rahmner; Birgit Eiermann; Seher Korkmaz; Lars L Gustafsson; Magnus Gruvén; Simon Maxwell; Hans-Georg Eichle; Anikó Vég
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

6.  Interpretation of clinical guidelines for poisoned patients: positive and negative effects of standard phrases used in TOXBASE.

Authors:  W S Waring; S H McDonald; A M Good; L D Gordon; D N Bateman
Journal:  Eur J Clin Pharmacol       Date:  2009-06-11       Impact factor: 2.953

7.  The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals.

Authors:  Hans C Ebbers; Aukje K Mantel-Teeuwisse; Fakhredin A Sayed-Tabatabaei; Ellen H M Moors; Huub Schellekens; Hubert G M Leufkens
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

Review 8.  The Quality and Reliability of Information in the Summaries of Product Characteristics.

Authors:  Ewelina Drelich; Urszula Religioni; Kevin Chung; Justyna Kaźmierczak; Eliza Blicharska; Agnieszka Neumann-Podczaska; Jerzy Krysiński; Piotr Merks
Journal:  Int J Environ Res Public Health       Date:  2022-02-15       Impact factor: 3.390

9.  Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.

Authors:  Victoria R Cornelius; Kun Liu; Janet Peacock; Odile Sauzet
Journal:  BMJ Open       Date:  2016-03-20       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.